Telix Pharmaceuticals Ltd. (Uplisting)(TLX)_个股概要_股票价格_最新资讯_行情走势_历史数据 - 老虎社区

应交易所要求，美/港股行情延时15分钟展示，下载APP即可免费查看实时行情。

关闭

TLX Telix Pharmaceuticals Ltd. (Uplisting)

休市中 01-09 16:00:00 EST

7.56

-0.07

-0.92%

盘后7.56

+0.000.00%

19:46 EST

最高7.71	最低7.52	成交量9.90万
今开7.71	昨收7.63	日振幅2.49%
总市值25.33亿	流通市值20.56亿	总股本3.35亿
成交额74.96万	换手率0.04%	流通股本2.72亿
市净率--	ROE--	每股收益0.00
52周最高--	52周最低--	市盈率--
股息--	股息收益率--	ROA--

数据加载中...

北京优虎网络科技有限公司

{"stockData":{"symbol":"TLX","market":"US","secType":"STK","nameCN":"Telix Pharmaceuticals Ltd. (Uplisting)","latestPrice":7.56,"timestamp":1767992400000,"preClose":7.63,"halted":0,"volume":99037,"hourTrading":{"tag":"盘后","latestPrice":7.56,"preClose":7.56,"latestTime":"19:46 EST","volume":6672,"amount":50848.548,"timestamp":1768006019145},"delay":0,"floatShares":272000000,"shares":335000000,"eps":0.03,"marketStatus":"休市中","change":-0.07,"latestTime":"01-09 16:00:00 EST","open":7.71,"high":7.71,"low":7.52,"amount":749554.998058,"amplitude":0.024902,"askPrice":0,"askSize":0,"bidPrice":0,"bidSize":0,"shortable":3,"etf":0,"ttmEps":0.03,"tradingStatus":0,"nextMarketStatus":{"tag":"盘前交易","tradingStatus":1,"beginTime":1768208400000},"marketStatusCode":7,"adr":0,"adrRate":1,"listingDate":1718337600000,"exchange":"NASDAQ","adjPreClose":7.63,"preHourTrading":{"tag":"盘前","latestPrice":7.72,"preClose":7.63,"latestTime":"09:29 EST","volume":414,"amount":3199.229712,"timestamp":1767968999050},"postHourTrading":{"tag":"盘后","latestPrice":7.56,"preClose":7.56,"latestTime":"19:46 EST","volume":6672,"amount":50848.548,"timestamp":1768006019145},"volumeRatio":0.7242079736512699},"requestUrl":"/m/hq/s/TLX","defaultTab":"news","newsList":[{"id":"2562128302","title":"美监管机构因发动机故障对本田启动调查 涉超140万辆汽车","url":"https://stock-news.laohu8.com/highlight/detail?id=2562128302","media":"格隆汇","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2562128302?lang=zh_cn&edition=full","pubTime":"2025-08-25 17:05","pubTimestamp":1756112725,"startTime":"0","endTime":"0","summary":null,"market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.gelonghui.com/rss/live/live.xml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"live_gelonghui","symbols":["BK4139","TLX"],"gpt_icon":0},{"id":"1195239442","title":"异动解读 | Telix Pharmaceuticals公布2024财年业绩大涨,盘中股价暴涨10%","url":"https://stock-news.laohu8.com/highlight/detail?id=1195239442","media":"异动解读","labels":["movement"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1195239442?lang=zh_cn&edition=full","pubTime":"2025-02-24 22:32","pubTimestamp":1740407544,"startTime":"0","endTime":"0","summary":"2025年2月24日,周一盘中,Telix Pharmaceuticals(TLX.US)股价大涨10%,引发市场广泛关注。\n\n此前,Telix公布了2024财年财报,财报显示公司2024财年净利润达到3293万美元,同比大涨851.73%。营业收入也同比增长54.79%至5.17亿美元,利润和收入双双大幅增长。\n\nTelix是一家开发治疗和成像癌症的放射性药物的生物制药公司。其主打产品Illuccix用于前列腺癌成像,在美国已实现大规模商业化销售。财报数据反映了公司业务高速增长的良好态势,有力增强了市场对公司长期发展前景的信心,成为推动股价暴涨的主要动力。","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":"异动解读 | Telix Pharmaceuticals公布2024财年业绩大涨,盘中股价暴涨10%","news_tag":"movement","news_rank":0,"length":0,"strategy_id":0,"source":"ai_movement_cn","symbols":["TLX"],"gpt_icon":0},{"id":"2513796469","title":"Telix Pharmaceutic2024财年实现净利润32.93百万美元，同比增加851.73%","url":"https://stock-news.laohu8.com/highlight/detail?id=2513796469","media":"市场透视","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2513796469?lang=zh_cn&edition=full","pubTime":"2025-02-24 11:01","pubTimestamp":1740366068,"startTime":"0","endTime":"0","summary":"2月24日，Telix Pharmaceutic公布财报，公告显示公司2024财年净利润为32.93百万美元，同比增加851.73%；其中营业收入为5.17亿美元，同比增加54.79%，每股基本收益为0.10美元。从资产负债表来看，Telix Pharmaceutic总负债5.92亿美元，其中短期债务13.30百万美元，资产负债比为1.60，流动比率为2.78。机构评级：截至2025年2月24日，当前有5家机构对Telix Pharmaceutic目标价做出预测，其中目标均价为21.96美元，其中最低目标价为21.04美元，最高目标价为22.95美元。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250224110119a25153b2&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":["earning"],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250224110119a25153b2&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["TLX"],"gpt_icon":0}],"profile":{"websiteUrl":"http://www.telixpharma.com","stockEarnings":[{"period":"1week","weight":-0.0079},{"period":"1month","weight":-0.2379},{"period":"3month","weight":-0.21},{"period":"6month","weight":-0.5266},{"period":"1year","weight":-0.5075},{"period":"ytd","weight":0.0093}],"compareEarnings":[{"period":"1week","weight":0.016},{"period":"1month","weight":0.0095},{"period":"3month","weight":0.0629},{"period":"6month","weight":0.113},{"period":"1year","weight":0.1774},{"period":"ytd","weight":0.0178}],"compareStock":{"symbol":"SPY","name":"标普500ETF"},"description":"Telix Pharmaceuticals Limited于2017年1月3日在澳大利亚注册成立。该公司是一家处于商业阶段的生物制药公司，专注于治疗和诊断放射性药物的开发和商业化。他们的使命是成为放射性药物的全球领导者，将治疗和诊断方式相结合，造福患者，这是一种创新的精准医学概念，通常被称为“治疗诊断学”。他们拥有广泛的治疗放射性药物候选产品线，重点是泌尿肿瘤学（前列腺和肾脏）、神经肿瘤学（神经胶质瘤）、肌肉骨骼肿瘤学（肉瘤）和骨髓调理。他们的治疗方法旨在将成像和治疗结合起来，“观察和治疗”癌症和罕见病，更好地为患者提供治疗决策和个性化治疗。","exchange":"NASDAQ","name":"Telix Pharmaceuticals Ltd. (Uplisting)","nameEN":"Telix Pharmaceuticals Ltd. (Uplisting)"},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"tenantId":"TBCN","deviceId":"web-server-community-laohu8-v3","version":"4.36.0","shortVersion":"4.36.0","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"Telix Pharmaceuticals Ltd. (Uplisting)(TLX)_个股概要_股票价格_最新资讯_行情走势_历史数据","description":"美港股上老虎。老虎社区提供Telix Pharmaceuticals Ltd. (Uplisting)(TLX)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","keywords":"Telix Pharmaceuticals Ltd. (Uplisting),TLX,Telix Pharmaceuticals Ltd. (Uplisting)股票,Telix Pharmaceuticals Ltd. (Uplisting)股票老虎,Telix Pharmaceuticals Ltd. (Uplisting)股票老虎国际,Telix Pharmaceuticals Ltd. (Uplisting)行情,Telix Pharmaceuticals Ltd. (Uplisting)股票行情,Telix Pharmaceuticals Ltd. (Uplisting)股价,Telix Pharmaceuticals Ltd. (Uplisting)股市,Telix Pharmaceuticals Ltd. (Uplisting)股票价格,Telix Pharmaceuticals Ltd. (Uplisting)股票交易,Telix Pharmaceuticals Ltd. (Uplisting)股票购买,Telix Pharmaceuticals Ltd. (Uplisting)股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"Telix Pharmaceuticals Ltd. (Uplisting)(TLX)_个股概要_股票价格_最新资讯_行情走势_历史数据","og_description":"美港股上老虎。老虎社区提供Telix Pharmaceuticals Ltd. (Uplisting)(TLX)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","og_image":"https://static.tigerbbs.com/a0b84b8debbbce3b4440f7fdd5eed2e7"}}}